KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Assets (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Current Assets for 17 consecutive years, with $2.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 4.1% to $2.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 billion, a 4.1% decrease, with the full-year FY2025 number at $2.9 billion, down 4.1% from a year prior.
  • Current Assets was $2.9 billion for Q4 2025 at Bio-Rad Laboratories, up from $2.8 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $3.3 billion in Q1 2022 to a low of $2.0 billion in Q4 2021.
  • A 5-year average of $2.9 billion and a median of $3.0 billion in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 58.65% in 2022, then fell 8.02% in 2025.
  • Bio-Rad Laboratories' Current Assets stood at $2.0 billion in 2021, then skyrocketed by 58.65% to $3.2 billion in 2022, then decreased by 3.47% to $3.0 billion in 2023, then decreased by 0.59% to $3.0 billion in 2024, then dropped by 4.1% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Current Assets are $2.9 billion (Q4 2025), $2.8 billion (Q3 2025), and $2.8 billion (Q2 2025).